Psoriasis and Mesenchymal stem/stromal cells (MSC): what the trial registry contains
The ClinicalTrials.gov registry holds 10 records for MSC in Psoriasis: 0 recruiting now, 0 labelled Phase 3 or 4, across 3 countries. Snapshot 2026-08-29.
Why this is studied in Psoriasis
Psoriasis is T-cell-driven skin inflammation with a well-mapped cytokine cascade, and biologics targeting that cascade produce large, reproducible clearance rates. Cell approaches target the same immune axis less specifically, so the comparator bar here is unusually high.
What MSC means in this table
Mesenchymal stromal cells are the workhorse of commercial cell therapy: easy to source from fat, cord or marrow, easy to expand, and rarely characterised in the same way twice. Their proposed action is paracrine — signalling molecules that damp inflammation — rather than replacement of lost tissue. That matters when reading counts like these, because two studies filed under the same label can test materially different products at different doses by different routes.
The numbers
Every figure below comes from one reproducible query (psoriasis x mesenchymal stem cell) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 10 |
| Interventional studies in the sample | 10 |
| Recruiting right now | 0 |
| Completed | 4 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 0 |
| Countries with at least one site | 3 |
| Median planned enrolment | 9 participants |
| Largest single planned enrolment | 57 participants |
| First / most recent start year | 2015 — 2022 |
How mature is this evidence?
The registry shows exploratory work only — 10 records, no Phase 3 or 4 label, 0 open to enrolment right now.
4 records are marked completed and 0 ended early (terminated, withdrawn or suspended): 0% of registrations did not run to plan.
| Phase label | Records | Share |
|---|---|---|
| Phase 1 | 8 | 53% |
| Phase 2 | 5 | 33% |
| Not applicable | 1 | 7% |
| Early Phase 1 | 1 | 7% |
Median planned enrolment is 9 participants (largest single study: 57). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
The work is distributed across 3 countries; China alone accounts for about 80% of mentions, so 'internationally researched' can still mean concentrated in a few regulatory environments.
| Country | Studies with a site there |
|---|---|
| China | 8 |
| Singapore | 1 |
| South Korea | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Among the top lead sponsors, 7 are universities or hospitals and 3 are companies, making this a academic area.
- Guangdong Provincial Hospital of Traditional Chinese Medicine — 5 records
- Affiliated Hospital to Academy of Military Medical Sciences — 1 record
- Central South University — 1 record
- Paracrine Therapeutics Dermatology Pte. Ltd. — 1 record
- Kang Stem Biotech Co., Ltd. — 1 record
- Tianjin Ever Union Biotechnology Co., Ltd. — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT04785027 — Comparison of PSORI-CM01 Formula vs Gu Ben Hua Yu Formula Combined With AD-MSCs in Psoriasis | Phase 1, Phase 2 | Unknown | 16 | Guangdong Provincial Hospital of Traditional Chinese Medicin | 2021-03-17 |
| NCT03745417 — Efficacy and Safety of Expanded UCMSCs On Patients With Moderate to Severe Psoriasis | Phase 1, Phase 2 | Unknown | 5 | Guangdong Provincial Hospital of Traditional Chinese Medicin | 2021-08-31 |
| NCT03392311 — Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis | Phase 1, Phase 2 | Completed | 8 | Guangdong Provincial Hospital of Traditional Chinese Medicin | 2019-07-23 |
| NCT03265613 — Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis | Phase 1, Phase 2 | Completed | 7 | Guangdong Provincial Hospital of Traditional Chinese Medicin | 2017-09-24 |
| NCT02491658 — Safety and Efficacy of UC-MSCs in Patients With Psoriasis Vulgaris | Phase 1, Phase 2 | Unknown | 30 | Affiliated Hospital to Academy of Military Medical Sciences | 2015-04 |
| NCT05523011 — Safety and Tolerability Study of MSC Exosome Ointment | Phase 1 | Completed | 10 | Paracrine Therapeutics Dermatology Pte. Ltd. | 2022-03-08 |
| NCT02918123 — Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis | Phase 1 | Unknown | 9 | Kang Stem Biotech Co., Ltd. | 2018-01-17 |
| NCT03424629 — Safety and Efficacy of UC-MSCs in Patients With Plaque Psoriasis | Phase 1 | Unknown | 57 | Tianjin Ever Union Biotechnology Co., Ltd. | 2018-06-01 |
| NCT04275024 — Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment and PSORI-CM01 Granule in Psoriasis Patients | n/a | Completed | 8 | Guangdong Provincial Hospital of Traditional Chinese Medicin | 2020-04-01 |
| NCT03765957 — Clinical Research on Treatment of Psoriasis by Human Umbilical Cord-derived Mesenchymal Stem Cells | Early Phase 1 | Unknown | 12 | Central South University | 2019-02-20 |
What this page does and does not tell you
Treat this as a map of research activity. It tells you whether a claim has an evidence programme behind it — not whether the treatment helped anyone.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many MSC studies for Psoriasis are recruiting right now?
0 of 10 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is MSC an approved treatment for Psoriasis?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 10 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on MSC for Psoriasis?
0 of 10 records carry a Phase 3 or Phase 4 label and 4 are marked completed. Registrations run from 2015 to 2022.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.